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Diabetic retinopathy (DR) is a leading cause of visual impairment worldwide. Patients with
DR may irreversibly lose sight as a result of the development of diabetic macular edema
(DME) and/or proliferative diabetic retinopathy (PDR); retinal blood vessel dysfunction and
degeneration plays an essential role in their pathogenesis. Although new treatments have
been recently introduced for DME, including intravitreal vascular endothelial growth factor
inhibitors (anti-VEGFs) and steroids, a high proportion of patients (~40–50%) do not respond
to these therapies. Furthermore, for people with PDR, laser photocoagulation remains a
mainstay therapy despite this being an inherently destructive procedure. Endothelial prog-
enitor cells (EPCs) are a low-frequency population of circulating cells known to be recruited
to sites of vessel damage and tissue ischemia where they promote vascular healing and
re-perfusion. A growing body of evidence suggests that the number and function of EPCs
are altered in patients with varying degrees of diabetes duration, metabolic control, and
in the presence or absence of DR. Although there are no clear-cut outcomes from these
clinical studies, there is mounting evidence that some EPC sub-types may be involved in
the pathogenesis of DR and may also serve as biomarkers for disease progression and
stratification. Moreover, some EPC sub-types have considerable potential as therapeutic
modalities for DME and PDR in the context of cell therapy. This study presents basic clini-
cal concepts of DR and combines this with a general insight on EPCs and their relation to
future directions in understanding and treating this important diabetic complication.
Keywords: diabetic retinopathy, diabetic macular edema, endothelial progenitor cells, ischemia, proliferative
diabetic retinopathy, retina, hematopoietic stem cells, vessels
DIABETIC RETINOPATHY
AWORLDWIDE DISEASE WITH INCREASING PREVALENCE
Diabetic retinopathy (DR) is the most common microvascular
complication of diabetes mellitus (DM) and a leading cause of
visual loss among individuals of working age (1, 2). Due to the
ever-increasing numbers of people with DM, principally the type
2 form of disease, it is expected that the burden of DR will continue
to rise. Indeed, it has been estimated that the worldwide prevalence
of DR will increase from 126.6 million in 2010 to 191 million by
2030 (3).
Diabetic retinopathy occurs more frequently in people with
poor glycemic control and with longer duration of diabetes (4).
Other major risk factors include hypertension (5), renal disease (6,
7), and dyslipoproteinemia (8, 9). The Diabetes Control and Com-
plications Trial (DCCT) (10) and the United Kingdom Prospective
Diabetes Study (UK-PDS) (5) demonstrated the importance of
keeping a tight glucose control on delaying the onset and slow-
ing the progression of DR in people with type 1 and type 2
DM, respectively. The UK-PDS demonstrated that maintaining
adequate levels of blood pressure (~140/80) reduced the risk of
DR in people with DM type 2 (5). Although HbA1c, an index
of prolonged hyperglycemia, remains the strongest risk factor
for predicting progression of DR, this parameter accounted for
only 11% of the risk of retinopathy in the DCCT (11). Further-
more,HbA1c,blood pressure,and total serum cholesterol, together,
accounted for only 9–10% of the risk of DR in the Wisconsin
epidemiologic study of diabetic retinopathy (WESDR) (12). The
situation continues to become ever-more complex, and recent evi-
dence suggests that sleep apnea (13, 14) and changes in serum
prolactin (15), adiponectin (16), and homocysteine (17) may affect
the progression of DR.
CLINICAL FEATURES AND CLASSIFICATION
The earliest retinal abnormalities detected in people with DM
appear to be functional in that they occur in a fundus, which
appears normal. Functional changes in the diabetic retina include
abnormal electroretinographic responses (18, 19), changes in
blood flow, and loss of autoregulatory mechanisms that adjust reti-
nal capillary perfusion (20). As DR progresses, microaneurysms,
retinal hemorrhages, hard exudates (lipid leakage), and “cotton
wool spots”(localized disruption of axoplasmic flow) may develop,
which are readily observed upon fundus examination. In late stages
of DR, venous beading (irregularity in the caliber of the retinal
veins with saccular dilations and thinning of the vein wall), intra-
retinal microvascular abnormalities (IRMA), and intra-retinal
and/or pre-retinal neovascularization will ensue.
Based on the absence or presence of neovascularization,
patients with DR are classified as having non-proliferative dia-
betic retinopathy (NPDR) or proliferative diabetic retinopathy
(PDR), respectively (Figure 1). The fundus of patients with severe
NPDR are typically characterized by the presence of retinal hem-
orrhage and/or microaneurysms in four retinal quadrants, venous
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FIGURE 1 | Fundus photographs obtained from patients with
non-proliferative diabetic retinopathy (NPDR) (A) and proliferative
diabetic retinopathy (PDR) (B). Note few hemorrhages and a cotton wool
spot at the superior aspect of the macula in (A), and marked neovessels in
the disc and macular exudation in (B).
beading in two retinal quadrants, or IRMA in one retinal quadrant
(known as the “4–2–1 rule”). These patients are at higher risk of
progression to PDR. At NPDR or PDR stages, there may be overt
breakdown of the inner and/or outer blood retinal barrier (BRBs)
with characteristic diabetic macular edema (DME) (Figure 2).
The accumulation of fluid at the center of the retina occurring
in DME constitutes the leading cause of visual loss among people
with DR.
VASCULAR ABNORMALITIES
The pathological sequence of retinal vessel abnormalities in DR
includes early and progressive thickening of the basement mem-
brane and dysfunction and loss of endothelial cells, pericytes, and
vascular smooth muscle [reviewed by Curtis et al. (21)]. Progres-
sive capillary non-perfusion and ensuing ischemia in the diabetic
retina may induce hypoxia-related up-regulation of cytokines and
growth factors, such as vascular endothelial growth factor (VEGF)
(22, 23), and this drives vasopermeability (DME) and/or abnormal
neovascularization (21).
FIGURE 2 | Fluorescein angiography obtained from the left eye of a
patient with diabetic macular edema and PDR. Note drop out of
perifoveal capillaries (A) with late leakage (B) and leakage from neovessels
at the disc (A,B).
The diabetic milieu is highly damaging to the retinal capillary
endothelium and this results in a significantly greater turnover
of these cells when compared to non-diabetic equivalents (24).
Exhaustion of endothelial cell replicative capacity and cells reach-
ing their so-called Hayflick limit (25) means that the retinal vas-
culature in diabetic patients has impaired regenerative capacity.
This underlines the progressive degenerative nature of DR in most
patients.
RETINAL ISCHEMIA AND DIABETIC RETINOPATHY
Retinal ischemia is involved in the occurrence of the two major
complications of DR, namely DME and PDR. Surprisingly, little
is known about the natural history of retinal ischemia in DR and
how it is modified by treatment. Ischemia can affect different areas
of the retina; its implications with regard to the development of
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FIGURE 3 | Fluorescein angiography obtained from the right eye of a
patient with non-proliferative diabetic retinopathy. Note diffuse retinal
non-perfusion and ischemia in the midperipheral retina in the absence of
neovascularization.
complications of DR may depend on this topographic distribution
and also on its extension. For example, a relatively small area of
ischemia affecting the perifoveal capillaries (“ischemic maculopa-
thy”) may have profound impact on vision. In contrast, a large
area of midperipheral retinal ischemia may not produce an imme-
diate change in sight but may trigger a neovascular response with
development of PDR and poor longer term outcomes. In certain
circumstances, very anterior (far peripheral) retinal ischemia, even
if limited, may give rise to anterior segment neovascularization
(rubeosis), including the development of neovascular glaucoma,
and a more guarded prognosis. It is not clear why in some patients
areas of retinal ischemia are mainly restricted to the macula,
whereas in others the retinal vasculature is relatively intact at the
macula but marked midperipheral retinal ischemia develops.
Clinically, retinal ischemia can be adequately identified, and its
extension measured, by means of fundus fluorescein angiography
(FFA) (Figure 3). For this imaging technique, a dye (fluores-
cein) is injected in a peripheral vein; images of the fundus are
obtained as the dye circulates through the retinal blood vessels.
Recently, new emerging technologies using wide-angle fundus
cameras have become available (26, 27). These allow obtaining
angiograms encompassing a 200-degree field of the retina in a sin-
gle shot with a nearly complete visualization of the whole retinal
vascular tree (Figure 4). Other new imaging techniques are being
developed, such as differential phase-contrast swept-source opti-
cal coherence tomography (OCT), which allows visualization of
retinal blood vessels without the need for injection of dyes (28–30).
Using FFA, spontaneous resolution of areas of retinal ischemia
in DR has been observed (31), although the mechanisms under-
pinning re-perfusion have not been elucidated. Currently, no
treatment has been identified that can reverse retinal ischemia
in DR. For example, the current treatment for PDR, laser pan-
retinal photocoagulation (PRP), aims at destroying the ischemic
retina rather than at reperfusing it. Furthermore, progression of
FIGURE 4 | Wide-angle fluorescein angiography obtained with the
Optos imaging system. Note excellent visualization of the vascular tree in
the posterior pole and midperipheral retina with a single short.
FIGURE 5 | Fundus photograph obtained from the left eye of a patient
with proliferative diabetic retinopathy who had undergone laser
panretinal photocoagulation (PRP). Despite a complete PRP, active
disease was still present, as demonstrated by the presence of still viable
neovascularization and extensive sub-hyaloid, pre-retinal hemorrhages.
Note the large pre-retinal hemorrhage covering the fovea.
the disease can still be observed following PRP (Figure 5). As
discussed below, circulating EPCs may play a role in vascular re-
perfusion and tissue regeneration. In addition, delivery of these
cells has emerged as an exciting potential therapeutic strategy for
retinal ischemia in DR.
ENDOTHELIAL PROGENITOR CELLS
Endothelial progenitor cells (EPCs) are circulating cells believed
to play an important role in tissue regeneration by promoting the
repair of blood vessels and aiding in the re-perfusion of ischemic
areas (32). EPCs generally account for only ~0.01% of circulat-
ing cells, although reported levels varied which may, once again,
www.frontiersin.org April 2014 | Volume 5 | Article 44 | 3
Lois et al. Endothelial progenitor cells in diabetic retinopathy
reflect on the variability on the cells measured (33). Their origin
remains somewhat uncertain; they may derive from hematopoietic
stem cells in the bone marrow and/or highly specialized vascular
stem cell niches in vessel walls or within the endothelium (34,
35). Controversy also exists with regard to the definition of an
EPC. Pre-clinical and clinical investigations evaluating the ther-
apeutic potential of EPCs have produced variable results, with
some studies showing favorable outcomes whereas others failed to
demonstrate success (36–39). It is likely that this variable response
observed in EPC therapy relates, at least in part, to the use of a
heterogeneous mixture of cells (not just EPCs) rather than being
explained by the lack of therapeutic potential of a well-defined,
efficacious EPC sub-type.
EPCs have been proposed as useful cell biomarkers of disease
(40). For both therapeutic and biomarker investigations to be suc-
cessful, it is essential that well-defined populations of EPCs are
used. It would be advantageous if agreement among researchers
in the EPC field could be reached, especially with regard to the def-
inition and terminology used to refer these cells and their various
sub-types. If the same type of EPCs were to be used for therapeutic
or prognostic purposes by researchers, comparisons among stud-
ies and pooling of their data, required to increase the power of
the evidence, would be possible, furthering the research into this
exciting area. As discussed below, unfortunately, this has not been
the case so far with regard to the existing literature on EPCs in DR.
DEFINING AN EPC
Groundbreaking research by Asahara et al. (32) first isolated
endothelial cell progenitors from human peripheral blood using
CD34 and Flk-1 (VEGF receptor 2, VEGF-R2) surface markers.
They determined that these cells were able to differentiate into
endothelial cells and incorporate into sites where active angiogen-
esis was taking place. Subsequent studies by other groups provided
supporting evidence on the existence of circulating EPCs (41–44).
As pointed above, controversy exists with regard to how to
define an EPC. In a very recent article, Basile and Yoder thoroughly
reviewed this issue and provided a useful perspective on the char-
acterization of EPCs (45). They suggested that evidence support
the concept that endothelial colony-forming cells (ECFC), also
known as outgrowth endothelial cells (OECs), display many fea-
tures of circulating cells that are consistent with the original criteria
set for an EPC. Basile and Yoder proposed the term pro-angiogenic
hematopoietic cells (PACs) to refer to cells that are not in-fact
endothelial progenitors but rather “adjuvants” in the process of
vascular repair. Our previously identified myeloid angiogenic cells
(MACs) would also fit with this definition. Thus, it is likely that
different populations of adjuvants cells may exist (see below). The
term “EPC” should not be used, hence, to refer PACs/MACs but
be restricted to true EPCs (for many researchers, ECFCs).
ECFCs are retrieved with greater efficiency from cord blood
compared with peripheral blood; indeed, the former source pro-
vides cells with higher proliferation rates and achieves significantly
more population doublings than those from peripheral blood (46).
A standard method for obtaining ECFCs is by in vitro culturing
of the mononuclear fraction of blood at high density on Type
1 collagen-coated plates (47). Using this technique and depend-
ing on whether they are isolated from cord blood or peripheral
FIGURE 6 | (A) Human endothelial colony-forming cells (ECFCs) grow in
culture as a cell monolayer and disclose a cobblestone appearance. Cells
form tight junctional complexes, shown by Z0-1 staining in green. Nuclei
labeled in blue with DAPI. (B) Human endothelial colony-forming cells
(ECFCs) (labeled in red) form tube-like structures with retinal microvascular
endothelial cells (labeled in green) in a 3D Matrigel in vitro model.
blood, ECFCs colonies appear between 2 and 5 weeks and dis-
play a characteristic cobblestone-shaped morphology (Figure 6)
(47). Research from our group using genome-wide transcrip-
tomics, proteomics, and ultrastructural evaluation has demon-
strated ECFCs intrinsic endothelial identity (48, 49). ECFCs have a
remarkably high proliferative capacity in comparison with mature
endothelial cells and maintain an endothelial phenotype with ex
vivo long-term expansion (49). ECFCs have robust clonogenic
potential, high telomerase activity, and in vitro and in vivo ves-
sel formation ability (45). Single-cell cloning of ECFCs demon-
strates a hierarchic regenerative potential with cells of high pro-
liferative potential (HPP) and low proliferative potential (LPP)
similar to what has been observed in hematopoietic stem cells
(34, 44). Ingram et al. (44) previously demonstrated that cord
blood-derived ECFCs possessed greater HPP (with concomitant
enhancement of telomerase activity) than ECFCs isolated from
peripheral blood. If ECFCs are to be utilized for regenerative
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medicine, it may be advantageous to isolate and use an ECFC
sub-population with HPP in order to achieve maximum cell
number expansion, if required.
ECFCs are positive for a range of endothelial cell mark-
ers, including VEGF-R2, VE-cadherin (CD144), CD31, CD105,
CD146, and Tie2; negative for hematopoietic cell markers such as
CD45, CD14, CD133, CD115, and demonstrate variable positiv-
ity to CD34 and CD117 (45, 50). Although evaluation of EPCs
has been undertaken widely using a combination of the above
cell markers by flow cytometry, as there is no specific antigen for
ECFCs, in vivo and in vitro functional evaluations are required
to identify specifically these cells. Thus, studies using only flow
cytometry would be determining “putative” EPCs.
In contrast to ECFCs, PACs are CD34+CD45+CD133+CD31+
CD14−CD235a− (45). Although circulating PACs may localize in
a peri-vascular manner at sites of vascular injury, they are not
able to integrate in the blood vessels as proper endothelial cells
(45). PACs have LPP but they do appear to contribute to vascular
repair by paracrine secretion of vasoactive molecules. Similar to
PACs, MACs do not populate vessel walls but are pro-angiogenic.
MACs are CD45+CD14+CD68+CD163+Tie2−, CD209−CD16−
(51). Therefore, as much of the previously conducted work on
“EPCs” was undertaken using cells that may not have fit strictly
with the above definition of an ECFC and may have been only
characterized by flow cytometry, data summarized below should
be interpreted with caution.
FUNCTIONAL PROPERTIES OF EPCs AND MODULATORY MECHANISMS
Functionally, EPCs present characteristics of endothelial cells (50).
Earlier studies emphasized the in vitro angiogenic potential of
EPCs, their ability to integrate into pre-existing vessels and de novo
tube formation (32, 43). Furthermore, several research groups,
including our own, have demonstrated that EPCs possess in vivo
potential for direct engraftment, aiding vascular repair and form-
ing well-perfused vasculature in various in vivo models (32, 43).
For example, the therapeutic potential of EPCs to treat retinal
ischemia following intravitreal injection was shown in a mouse
model of ischemic retinopathy in which ECFCs homed specifically
to ischemic retina and integrated directly within the host vascu-
lature (50). Importantly, these cells assisted in vascular remodel-
ing by forming vascular tubes with subsequent reduction in the
area of retinal ischemia and a concomitant increase in normal
vasculature (50).
In response to hypoxia, EPCs have the ability to mobilize
from their resident niche into the circulating blood and home
to ischemic tissues. The mechanisms by which EPCs mobilize
and specifically home to areas of ischemia are highly complex
and incompletely understood. They involve a range of path-
ways and stimulatory factors such as EPO (52), VEGF (53), and
G-CSF (54) but it also appears that signals released from apop-
totic endothelial cells are important for EPC recruitment to sites
of vascular damage (55). Since the homing process is hypoxia-
mediated, it is unsurprising that HIF-1α appears to be crucial
for EPC recruitment to sites of vascular insufficiency (56). On
sensing low oxygen levels, HIF-1α induces transcription of SDF-
1 and its receptor CXCR4, these known to be essential for EPC
migration and adhesion to specific areas of ischemic damage (56).
Blocking the CXCR4/SDF-1 signaling pathway inhibits EPC hom-
ing and results in their attenuated participation in promoting
vascularization (57).
Several factors appear to influence the occurrence and circulat-
ing levels of EPCs. These include age (58) and gender (59) with
younger women having higher numbers of EPCs. Physical activity
also increases numbers of EPCs, especially intense exercise (60). A
circadian rhythm on EPC release has been identified with higher
levels of EPCs circulating in the morning than in the evening (61).
Hypertension, diabetes, smoking habits as well as medications,
including statins, angiotensin-converting enzyme inhibitors, and
insulin may also affect the production and release of these cells
into the circulation (40, 62).
EPCs IN DIABETES AND DIABETIC RETINOPATHY
Accumulating evidence supports the concept that both type 1 and
type 2 diabetic patients have altered numbers of circulating EPCs
(63–65) and, when isolated, show dysfunctional responses includ-
ing impaired vasoreparative potential and premature senescence
(65, 66). Conflicting results, however, have been reported with
regard to the levels of circulating EPCs in people with diabetes.
Thus, reduced (63), increased (67), or unchanged (68, 69) levels of
EPCs compared with those observed in healthy age-matched vol-
unteers have been found in previous studies using flow cytometry
techniques. Similarly, although a reduced potential for EPCs to
grow in cultures derived from monocytes obtained from periph-
eral blood was found by some investigators (64, 65, 70), others
observed enhanced growth potential when EPCs were isolated
from diabetic patients with PDR (67) (see below). Poor glycemic
control, as determined by HbA1c levels, appears to be associated
with a reduction in numbers of circulating EPCs whereas an ade-
quate control of glycemia seems to increase their numbers (64).
Beyond the presence of diabetes, a relatively scarce number of stud-
ies have been conducted evaluating EPCs specifically in patients
with DR (Table 1) (67–69, 71–74). A summary of these follows.
Clinical studies on EPCs and DR
In a cross-sectional study including 60 type 2 diabetic patients
with and without peripheral arterial disease and with and without
severe NPDR and PDR (DR−/PAD− n= 15, DR−/PAD+ n= 30,
DR+/PAD− n= 5, and DR+/PAD+ n= 10), Fadini and collabora-
tors (69) identified reduced levels of CD34+ cells in patients with
DR when compared with those without it. No differences in levels
of CD34+/KDR+ (KDR=VEGF-R2) cells between these groups
were, however, found. Patients with peripheral arterial disease had
reduced levels of CD34+/KDR+ cells.
Lee and colleagues (73) evaluated, in a cross-sectional study,
the concentration of circulating EPCs, defined as CD34+ cells
or c-Kit+ cells, in a group of 45 type 2 diabetic patients and
compared them with those observed in 15 age- and gender-
matched control subjects. Patients were classified as having no DR
(n= 15), NPDR (n= 15), or PDR (n= 15). Circulating CD34+
cell numbers were higher in diabetic patients compared with con-
trol subjects and increase with increasing staging of the disease
(PDR>NPDR> no DR).
Brunner and collaborators (71) undertook a case–control
cross-sectional study, which included 90 patients with type 1
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DM with no DR (n= 30), mild NPDR (n= 30), moderate
to severe NPDR (n= 10), mild to moderate PDR (n= 10),
and high-risk PDR (n= 10). The study included an age-,
gender-, and body-mass index-matched control group (n= 30).
CD34+/CD133+ (which they labeled“circulating progenitor cells”
or “CPCs”), CD34+/CD133+/CD309+ (labeled as “EPCs”), and
CD34+/CD133+/CD309+/CD31+ (labeled as “mature EPCs” of
“mat-EPCs”) were measured. When compared with diabetic
patients without DR, levels of CPCs, EPCs, and mat-EPCs were
found to be reduced in NPDR; EPCs and mat-EPCs were found
to be increased in PDR. EPC and mat-EPC number was reduced
in patients with diabetes when compared with healthy subjects. As
a more recent follow-up, this group expanded their observations
to a group of 126 patients with type 2 diabetes, with or with-
out macrovascular disease and with no DR (n= 55), mild NPDR
(n= 19), moderate to severe NPDR (n= 16), early PDR (n= 19),
and high-risk PDR (n= 17) (72). In contrast to their previous
findings, they failed to detect statistically significant differences in
EPC numbers in patients with type 2 diabetes without macrovas-
cular disease at different stages of DR. However, in patients with
macrovascular disease, EPCs declined with advancing stages of
retinopathy.
Liu and colleagues (75) examined type 2 diabetic patients with
DR (severe NPDR and PDR, n= 20), type 2 diabetic patients with
peripheral arterial disease (n= 20), and healthy age- and gender-
matched volunteers (control group, n= 20) and found increased
levels of circulating EPCs in patients with DR when compared
with the control group. EPCs were defined as CD133+/CD34 +
cells, as determined by flow cytometry. An increase in early EPC-
CFU (colony-forming units) count was also observed in patients
with DR. Serum levels of nerve growth factor (NGF) and brain-
derived neurotrophic factor (BDNF) were found to be increased
in patients with DR and correlated with levels of circulating EPCs.
Tan and collaborators (67) undertook a study on a group
of 23 diabetic patients, type 1 (n= 9) and type 2 (n= 13)
(n= 1 not determined) with PDR and 22 healthy controls.
The great majority of patients (95%) had received PRP. They
found that the number of circulating ECFCs, determined as
CD34+/CD45− cells by flow cytometry, was increased in PDR.
Furthermore, mononuclear cells obtained from patients who
had PDR were more likely to grow ECFC colonies in cul-
ture than those obtained from healthy controls. ECFCs from
patients with PDR demonstrated reduced migration (PDR n= 2)
and reduced incorporation into vascular tubes (PDR n= 3)
in vitro. Microarray analysis of ECFCs from patients with PDR
(n= 2) demonstrated up-regulation of thrombospondin-1 and
tissue inhibitor of matrix metalloproteinases-3 (TIMP-3); west-
ern blotting confirmed increased levels of both proteins in ECFC
lysates.
Lombardo and associates (68) did not find a significant
reduction in the number of EPCs (CD34+/CD133+/VEGF-
R2+) in patients with type 2 diabetes when compared with
those from a group of healthy individuals (control group). Sub-
sets of patients with diabetes with or without angiopathy were
found to have significantly higher numbers of what was termed
pre-EPCs (CD34+/CD133+/CD117+). However, numbers of
CD31+/VEGF-R2+/VE-cadherin+ cells (CD144+), termed by the
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authors “late-EPCs,” were reduced in patients with diabetes type
2 recently diagnosed (within 1 year of diagnosis) with no clini-
cal evidence of angiopathy (n= 27) and in those with peripheral
arterial occlusive disease and DR (severe NPDR or PDR) (n= 27)
when compared with the control group (n= 24). The number of
circulating endothelial cells, matured endothelial cells thought to
sloughed off from the vascular intima, where increased in diabetic
patients.
Zerbini and colleagues (74) evaluated three groups of type
1 diabetics, with long-standing (≥23 years; n= 17) and short-
standing (≤7 years; n= 19) diabetes and no retinopathy and with
NPDR (diabetes of ≤20 years standing; n= 20). A group of age-
and gender-matched healthy volunteers were also included for
each of the above (with n= 17, 12, and 18 subjects, respectively).
No differences were found in levels of CD45−/CD34+/VEGF-
R2+ cells between the above different groups studied. However,
the number of colonies formed in the Hill assay was increased
in patients with NPDR when compared with those in the con-
trol group. Patients with milder retinopathy tended to form more
colonies than patients with more severe retinopathy. In patients
with long-standing diabetes and no retinopathy, the colony counts
were similar to those in control subjects.
The interpretation of the previously presented findings is
challenging. For instance, both high (67, 71) and low (69, 72)
levels of circulating EPCs have been reported in patients with
severe NPDR and PDR when compared with those in individuals
with no or mild retinopathy and with healthy subjects with-
out DM. It is possible that discrepancies observed may relate
to methodological differences among studies, specifically, and as
underlined above, the different criteria used to define an EPC.
Other factors need to be taken into consideration. Some stud-
ies included small number of subjects (67–69, 73–75), especially
when grouped in the different disease progression categories (68,
71–75), which may have had an effect on the statistical eval-
uation of the data (a sample power calculation was not given
in any of the above studies). All published studies on the sub-
ject have been cross-sectional (67–69, 74, 75) and, subsequently,
truly unable to evaluate the influence of changes in EPCs in
relation to disease progression. Few addressed the relationship
between number/function of EPCs and severity of DR (71–73)
and none attempted to relate them to the presence/extension of
retinal ischemia, as determined by using imaging modalities such
as fluorescein angiography. As retinal ischemia would seem to
be a main driver for eliciting a vasoregenerative response led by
EPCs, correlating the latter with retinal ischemia would seem fun-
damental. In this regard, prospective longitudinal studies from
our own laboratory are underway to address the relationship
between retinal ischemia and the EPC response. As information
with regard to flow cytometry techniques used in these studies
was limited, variability in methodological aspects of flow cytom-
etry could have also accounted for inconsistencies in the results
observed.
POTENTIAL USE OF EPCs IN DIABETIC RETINOPATHY
Endothelial progenitor cells could be potentially used in the man-
agement of patients with DR with two different purposes: (1) as
cell biomarkers or “prognosticators” and (2) as a potential therapy.
EPCs AS BIOMARKERS OF DISEASE SEVERITY
Endothelial progenitor cells have been proposed as useful bio-
marker for cardiovascular events and cancer progression (76, 77).
In a similar manner, it is possible that EPC number/function could
be used to predict which individuals may be at higher risk of losing
sight from DME or PDR. Prospective adequately powered cohort
studies would be needed to elucidate the potential use of EPCs as
cell biomarkers for DME and PDR and take into account other
risk factors and variables known to potentially affect retinopathy.
It is possible that other cells besides those strictly defined as EPCs
(for many, ECFCs) may be used for this purpose. As identification
of ECFCs in culture requires a period of around 4–6 weeks, this
strategy may be less practical and appealing than evaluating levels
of other circulating cell types by flow cytometry. Research in this
area could prove fruitful as predicting individuals at higher risk
of visual loss would be extremely helpful to the currently over-
stretched DR screening programs and health care systems. This
would allow a personalized follow-up strategy based on the indi-
vidual’s risk of progression and would avoid close follow-up with
the benefit to patients and health care systems.
EPCs AS A POTENTIAL THERAPY TO TREAT DR
The potential use of EPCs to treat DR is exciting but extensive
work is required before they could be introduced in clinical prac-
tice. Firstly, the type of cell(s) to be used and the number of
cells required should be determined. If a cell, alone, were to be
used for therapeutic purposes, those with the highest reparative
potential (i.e., ECFCs) may be chosen. Although not the sub-
ject of this review, pericyte progenitor cells (PPCs) have been
recently recognized (78, 79). As both, endothelial cells and per-
icytes are affected in DR, it would seem reasonable to consider
the possible administration of both progenitors in order to treat
this vascular disorder. Recently, Lee and co-workers (80) demon-
strated that CD34− cells may modulate the inherent characteristics
and behavior of ECFCs. They showed in vitro that ECFCs arising
from cultures in which CD34+ and CD34− cells are present (to
which they referred to as “hybrid ECFCs”) have higher prolifer-
ation capacity and slower senescence than those ECFCs grown
in cultures lacking CD34− cells (which they referred to as stem-
ECFCs). The later, however and importantly, demonstrated higher
endothelial cell differentiation. Both cell types (hybrid ECFCs and
stem-ECFCs), expressed ECFC surface markers, including CD133,
VEGF-R2, CXCR4, and c-kit) but did not expressed hematopoi-
etic lineage markers (CD11b, CD14, CD45). Before CD34− cells
are used to condition ECFCs prior to treatment (80) it would
be important to determine that these ECFCs do not have an
increased ability to form “neovessels.” Whereas in other organs
“neovascularization” may be beneficial, for instance in the heart,
this would not be the case in the retina where “revascularization”
or “healing” of pre-existing blood vessels rather than neovas-
cularization should be sought. Other cells may be also consid-
ered. As PACs are likely to act as adjuvants in the process of
“vascular regeneration,” further consideration to administering
these, in addition, should be given. However, the possibility for
PACs to develop into pro-inflammatory cells, which could have
potentially a deleterious effect in the retina, should be cautiously
balanced.
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Secondly, the number of cells required would need to be esti-
mated. It is likely that it would depend on the route of adminis-
tration selected as well as on the stage of disease at which patients
are planned to be treated. The route of administration will need
to be carefully chosen. Local delivery into the eye by means of
intravitreal injections would be an option, as many clinical trials
(81–84) using anti-VEGF therapy (Ranibizumab, Bevacizumab,
and Aflibercept) have demonstrated their safety even when admin-
istered monthly. However, considering the fact that DR often
affects similarly both eyes and that DM is a systemic disorder
in which other organs besides the eye are affected and may benefit
from this therapy, systemic administration should not be ruled
out. Systemic administration, if safe, could be given repeatedly, if
required, and at an early stage of disease.
Thirdly, the population most likely to benefit from treat-
ment with EPCs should be defined. EPCs could be used in an
attempt to re-vascularize areas of retinal ischemia in patients
who have already developed retinal vessel dropout as deter-
mined by fluorescein angiography. They could be used also to
improve retinal vessel function in patients with increase ves-
sel permeability and subsequent DME with or without retinal
ischemia being present. If the balance between beneficial effects
and side effects were to be appropriate, EPCs could be used
even at very early stages of retinopathy, before marked retinal
vessel abnormalities occurred in an attempt to abort progres-
sion to sight threatening complications. Alternatively, maneuvers
aimed at increasing levels of circulating endogenous EPCs, by
stimulation of the bone marrow and other EPC niches, and
their homing to sites where needed (i.e., retina) would be an
appealing option.
Fourthly, the most appropriate outcome measures that would
allow treatment effects to be determined in clinical trials should
be sought. For instance, if ECFCs adequately incorporate into
damaged retinal blood vessels in ischemic retina oxygen levels
in retinal veins may be expected to drop, as it has been shown
that there is increased oxygen saturation in people with DR (85,
86), which may relate, at least partially, by the poor distribution
of blood to retinal tissue result of capillary dropout. Fluorescein
angiography and, in the future, when fully developed for clinical
use, differential phase-contrast swept-source OCT may be able
to provide adequate information with regard to ECFCs incor-
poration to retinal vessel walls by demonstrating the presence
of capillaries in retinal areas were prior to treatment were not
present and, in the case of the former, by demonstrating improve
circulation in previously ischemic areas. Retinal functional stud-
ies, such as multifocal ERG responses, may be able to deter-
mine improved responses in those areas where revascularization
takes place.
Lastly but importantly, potential side effects of the treatment
will need to be carefully evaluated. Data from available completed
clinical trials, however, suggests that ECFCs should be safe for
clinical use.
CONCLUSION
Available data suggests EPCs are essential on maintaining reti-
nal vessel integrity and homeostasis. While some patients seem
to have inherent regenerative capacity, the molecular and cellular
basis for this has not been demonstrated. It seems likely that high
levels of reparative cells could underpin less risk of DR progression.
However, the precise role of EPCs in DR remains to be determined.
Experimental and adequately powered prospective cohort clinical
studies are required to better understand the possible role of EPCs
in the occurrence and progression of this disease. The possibility
of using EPCs as cell biomarkers of the sight threatening compli-
cations of DR, namely DME and PDR and as cell therapy is an
exciting one. Given the complexity of DM and DR, with multiple
factors modulating disease progression, a joint effort by multidis-
ciplinary research teams is likely to be needed in order to achieve
this goal.
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